Retina and liver fibrosis screening for patients with type 2 diabetes DOI
Yun-Chu Chen, Chun‐Jen Liu, Tung‐Hung Su

и другие.

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2025, Номер 10(5), С. 412 - 413

Опубликована: Апрель 9, 2025

Язык: Английский

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies DOI Creative Commons
Bufu Tang,

Wangting Xu,

Shiji Fang

и другие.

Military Medical Research, Год журнала: 2025, Номер 12(1)

Опубликована: Янв. 27, 2025

Abstract Background Radiofrequency ablation (RFA) is an efficient treatment with unlimited potential for liver cancer that can effectively reduce patient mortality. Understanding the biological process related RFA important improving strategy. This study aimed to identify critical targets regulating efficacy of RFA. Methods The in hepatocellular carcinoma (HCC) tumor models vivo, was analyzed by RNA sequencing technology. heat vitro HCC cells also constructed explore mechanism after cells. Nanoparticles high affinity were applied as a new therapy interfere expression maternal embryonic leucine zipper kinase (MELK). Results It found upregulated MELK expression, and inhibition promoted immunogenic cell death antitumor response, including anti-tumoral macrophage polarization increased CD8 + T cytotoxicity HCC. Mechanically, binds fatty acid-binding protein 5 (FABP5), affects its ubiquitination through K48R pathway increase stability, thereby activating B (Akt)/mammalian target rapamycin (mTOR) signaling axis weaken RFA-mediated effect. In addition, synthesis arginylglycylaspartic acid (RGD)-lipid nanoparticles (LNPs) targeting cell-intrinsic enhanced Conclusion therapeutic HCC, via RGD-LNPs provides insight into clinical combating malignant progression cancer.

Язык: Английский

Процитировано

0

Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and concurrent MASLD DOI
Jian Wang, Shaoqiu Zhang, Chuanwu Zhu

и другие.

Journal of Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0

Dyslipidemia and female reproductive failures: perspectives on lipid metabolism and endometrial immune dysregulation DOI
Yuan Zhang, Meshari A. Alzahrani, Svetlana Dambaeva

и другие.

Seminars in Immunopathology, Год журнала: 2025, Номер 47(1)

Опубликована: Фев. 18, 2025

Язык: Английский

Процитировано

0

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues DOI Open Access
Tyng‐Yuan Jang,

Yuting Zeng,

Po‐Cheng Liang

и другие.

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 19, 2025

ABSTRACT Background and Aims Air pollution is associated with advanced liver fibrosis in patients chronic diseases, including hepatitis B (CHB). This study aimed to investigate the association between air mortality CHB treated nucleotide/nucleoside analogues. Methods We enrolled 697 analogues analysed incidence risk factors for mortality. Daily pollutant concentrations were estimated from year before enrolment. Results All‐cause showed an annual of 1.1/100 person‐years after a follow‐up period 3798.1 person‐years. Factors strongest all‐cause cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 3.95/1.69–9.23; p = 0.02), age ([HR]/CI: 1.07/1.03–1.17, < 0.001) pre‐treatment gamma‐glutamyl transferase (GGT) levels (HR/CI: 1.004/1.001–1.006, 0.004). Among cirrhosis, 1.08/1.04–1.12, 0.001), GGT 1.004/1.001–1.008, 0.01), platelet count 0.988/0.977–0.998, 0.02) NO x concentration (per unit increment, ppb) (1.045/1.001–1.091; 0.046). The best cut‐off value predicting was 25.5 ppb (AUROC 0.63; 0.03). > higher (HR/CI:2.49/1.03–6.02; 0.04). Conclusions influences receiving analogue therapy. Long‐term exposure may increase liver‐related treatment.

Язык: Английский

Процитировано

0

Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword DOI
Shang‐Chin Huang, Tung‐Hung Su

Journal of Hepatology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0

Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider? DOI
Shang‐Chin Huang, Jia‐Horng Kao

Expert Review of Gastroenterology & Hepatology, Год журнала: 2025, Номер unknown, С. 1 - 5

Опубликована: Март 9, 2025

Introduction Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only small subset of patients. Current oral antiviral agents effectively suppress viral replication but fail to eliminate the virus (HBV). Recent advances immunomodulatory therapies offer new hope for improving rates.

Язык: Английский

Процитировано

0

Retina and liver fibrosis screening for patients with type 2 diabetes DOI
Yun-Chu Chen, Chun‐Jen Liu, Tung‐Hung Su

и другие.

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2025, Номер 10(5), С. 412 - 413

Опубликована: Апрель 9, 2025

Язык: Английский

Процитировано

0